Anzeige
Mehr »
Login
Dienstag, 28.06.2022 Börsentäglich über 12.000 News von 664 internationalen Medien
Breaking News! Kickt „Yumy Bear" die Konkurrenz aus den Shops?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 ISIN: US1101221083 Ticker-Symbol: BRM 
Tradegate
28.06.22
19:57 Uhr
74,72 Euro
-0,89
-1,18 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
74,5574,7020:37
74,4874,7820:37

Aktuelle News zur BRISTOL-MYERS SQUIBB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:58Canada approves Bristol-Myers' Opdivo for bladder cancer patients with certain conditions2
15:35Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo6
04:20Bristol-Myers Squibb (BMY) Stock: Why It Increased 1.29% Today10
BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln
02:35BMS cancer drug's expanded approval gives it an edge over a Gilead cell therapy17
MoAs court case looms, Bristol Myers Squibb touts label expansion for Breyanzi6
MoNew York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters6
MoBristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion5
MoFederal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit3
MoBristol Myers loses bid to toss $6.4B CVR lawsuit tied to Celgene takeover, Breyanzi approval12
MoBristol Myers Squibb announces positive trial results for treatment of MS8
FrBristol-Myers Squibb bid to dismiss $6.4B lawsuit from Celgene shareholders denied - Reuters18
FrHot Stocks: Cruise stocks jump; CAMP plunges on earnings; BMY, LLY set 52-week highs; ZEN buyout10
FrThis Is What Whales Are Betting On Bristol-Myers Squibb7
FrBristol-Myers MS drug linked to better COVID response with mRNA shots5
FrBristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis434Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume...
► Artikel lesen
FrBristol-Myers Squibb hits 52-week high; shares up 27% YTD6
21.06.BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's13
21.06.Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation13
20.06.European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy342Application based on Phase 3 TRANSFORM study in which Breyanzi outperformed the current standard of care with demonstrated statistically significant improvement in event-free survival and a well-established...
► Artikel lesen
17.06.Bristol Myers petitions the Supreme Court in a final bid to prove Gilead's Kite infringed on CAR-T patents22
Seite:  Weiter >>
493 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,17